Howard Morrison Joins Vendormate Board of Directors

ATLANTA, June 4 // -- Vendormate, the market leader in vendor management and credentialing, has appointed Howard Morrison as its newest board member.

"Howard's varied career has consistently placed him at the intersection of technology, finance, and entrepreneurism," said Andy Monin, Chairman and CEO of Vendormate. "His insight and participation will inspire Vendormate to continue its growth momentum and to open new lines of business."

Mr. Morrison's current professional activities include serving on the boards of Digitel Corporation and Quadrant Financial Corporation, an affiliate of First Chatham Bank. During late 2008 Mr. Morrison co-founded Lansera Group and its subsidiary, Energy Launch Partners, with Ross Harding, to identify and commercialize the latest technologies specifically in the areas of biomass to energy and water conservation.

"I've been involved with many high-growth technology opportunities in my career," said Mr. Morrison. "Vendormate epitomizes the convergence of all the right factors - talent, vision, insight, and action."

Mr. Morrison's banking career spanned nearly 30 years including being the chief financial officer of the NYSE listed Citizens and Southern Realty Investors (Southmark Properties) and in helping to develop the C&S Bank's (now Bank of America's) High Technology Banking Group and Atlanta's high technology business community.

Mr. Morrison currently serves as a board member of numerous technology and education organizations, including the Georgia Tech Research Corporation, Georgia Tech Applied Research Corporation and Georgia Tech Ireland, Georgia Southern University's Allen E. Paulsen College of Science and Technology, and Savannah State University's College of Science and Technology.

He has received numerous awards for his extensive involvement in community affairs including:

• Named "Leader of the Decade" by the Business & Technology Alliance
• Inducted into Georgia High Technology Hall of Fame
• Inducted into Savannah Business Hall of Fame
• Named one of Savannah's Power Players by The South magazine for positive community change
  

About Vendormate, Inc.

Vendormate protects the health of supply chains with a unique vendor credentialing and compliance monitoring solution. The program assures compliance with both internal policies and government mandates, including HIPAA and Deficit Reduction Act. Registered vendors are screened and rated by custom criteria and continuously monitored for non-compliance. An integrated badge feature controls access to facilities. Call 1-877-483-6368. Visit www.vendormate.com or vendorcompliance.wordpress.com.

SOURCE Vendormate, Inc

I-Therapeutix, Inc. Closes $15 Million Financing

WALTHAM, Mass., June 19 // -- I-Therapeutix announced today that it has closed a $15 million dollar Series C financing. The round was led by Polaris Venture Partners in Waltham, MA, with continued participation by existing investors, Versant Ventures and SV Life Sciences.

The proceeds will be used to commercialize I-ZIP(R) Ocular Bandage in the United States and to develop sustained drug delivery products for treatment of ophthalmic diseases and ocular infections.

"We are excited about working with I-Therapeutix to meet significant medical needs in ophthalmology. The company offers a combination of an experienced team with a successful track record, outstanding technology and product opportunities and a compelling business model," said Alan Crane, General Partner at Polaris Venture Partners, who will join the company's Board of Directors.

"In a financing environment that has been challenging for MedTech companies, we welcome the new vote of confidence by Polaris Venture Partners. We look forward to working with our investors to continue building a solid ophthalmic company," commented I-Therapeutix President and CEO, Amar Sawhney.

About I-Therapeutix, Inc:

I-Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. I-Therapeutix is also developing sustained ocular drug delivery vehicles utilizing its proprietary hydrogel polymer technology. The company was founded in November, 2006. The I-ZIP Ocular Bandage has already gained CE Mark approval and is undergoing pivotal clinical investigation in the United States.

About Polaris Venture Partners:

Polaris Venture Partners is a partnership of experienced investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. Polaris invests in businesses across a number of markets including life sciences, digital media, technology, consumer, and enertech. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 115 companies. Polaris-backed successes in life sciences include Adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), Alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA), and Transform Pharmaceuticals (sold to Johnson & Johnson). Current and former portfolio companies in technology, digital media and consumer include: Akamai Technologies, Allaire, Art.com, Athletes' Performance, HealthCentral Network, JibJab, LogMeIn, Powersoft, Quantcast, Solidworks, TechTarget and WordPress.

SOURCE I-Therapeutix, Inc.